Adherium Cash Flow per Share
Operating Cash Flow per Share of Adherium (ADR.AX) as of Oct 31, 2026.
Get this data via API
Financial Data API
Cash Flow per Share
-0.00AUD
YoY
-99.26%
Last updated:
Operating Cash Flow per Share of Adherium is 2026 -0.00 AUD. Operating Cash Flow per Share of Adherium was 2025 -0.42 AUD. It decreases by -99.26% higher compared to the previous year.
The Adherium Cash Flow per Share history
3 Years
10 Years
25 Years
Max
Cash Flow per Share
Date
Cash Flow per Share
Jan 1, 2019
-78.02 AUD
Jan 1, 2020
-12.94 AUD
Jan 1, 2021
-0.06 AUD
Jan 1, 2022
-3.49 AUD
Jan 1, 2023
-2.71 AUD
Jan 1, 2024
-1.40 AUD
Jan 1, 2025
-0.42 AUD
Jan 1, 2026
-0.00 AUD
| YEAR | Cash Flow per Share | YoY |
|---|---|---|
| -0.00AUD | -99.26% | |
| -0.42AUD | -69.77% | |
| -1.40AUD | -48.30% | |
| -2.71AUD | -22.36% | |
| -3.49AUD | +5,346.86% | |
| -0.06AUD | -99.51% | |
| -12.94AUD | -83.41% | |
| -78.02AUD | +14.28% | |
| -68.27AUD | -15.97% | |
| -81.25AUD | +41.52% | |
| -57.41AUD | -25,910.99% | |
| 0.22AUD | -1,363.22% | |
| -0.02AUD | — |
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Adherium Stock analysis
What does Adherium do? Adherium Ltd develops and supplies connected medical devices and respiratory medications for patients, pharmaceutical companies, healthcare providers, and contract research organizations. The company generates revenue through its Hailie sensor technology and cloud-based data platform, which provides real-time feedback on patients' use of inhaled medication. The Hailie Remote Patient Management (RPM) Solution, Hailie Sensors, and Hailie Solution are key products sold to healthcare providers, payers, and pharmaceutical companies. These solutions enable optimal management of severe asthma and COPD, reduce healthcare costs, and offer remote monitoring capabilities for patients and physicians.
The Hailie Sensor technology wraps around inhalers and connects via Bluetooth to capture medication use data, which is transmitted to the cloud-based Hailie platform. This platform delivers real-time feedback to patients through the Hailie app and to physicians via the Hailie portal. The company's focus on patient medication adherence and remote monitoring drives demand from healthcare providers seeking to improve treatment outcomes and from pharmaceutical companies aiming to enhance patient engagement with their respiratory medications.
Adherium's products target segments including patients with severe asthma and COPD, healthcare providers managing chronic conditions, payers interested in cost reduction, and pharmaceutical companies developing respiratory medications. The company's revenue model centers on selling its sensor technology, cloud platform access, and integrated RPM solutions to these key segments, leveraging FDA-cleared devices to ensure compliance and reliability in healthcare settings. Adherium is one of the most popular companies on Eulerpool.
Frequently Asked Questions about Adherium stock
On Eulerpool you can find the complete historical development of Operating Cash Flow per Share Adherium since 2006 – with annual values, charts, and detailed analysis.
Operating cash flow per share measures the operating cash generated per outstanding share.
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Cash Flow — Adherium
Operating Cash FlowCapital ExpendituresFree Cash FlowFCF per ShareDividends PaidShare BuybacksInvesting Cash FlowFinancing Cash FlowCapEx / RevenueCash Flow per ShareStock-Based CompensationChange in Working CapitalAcquisitions (Net)Net Change in CashCapEx/OCFFCF/Net IncomeFCF ConversionCash ConversionTotal Shareholder PayoutCapEx/D&A
All Key Metrics — Adherium
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth